PSTX News and Press, Poseida Therapeutics Inc. From 10/21/20

Poseida Therapeutics ([[PSTX]] -0.1%) and TScan Therapeutics have entered into a research collaboration and license agreement to explore development of TCR-T cell therapies for the treatment of COVID-19.Poseida's allogeneic T cell platform will be used in combination with TScan's immunodomina...

Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19 Partnership Leverages TScan's Proprietary High-throughput TCR/Target Discovery Platform and ...

Poseida Therapeutics (NASDAQ: PSTX )  to join the small cap Russell 2000 index, effective at the open today. More news on: Poseida Therapeutics, Inc., Renaissance Capital Greenwich Funds - Renaissance IPO ETF, Read more ...

SAN DIEGO , Sept. 18, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cu...

SAN DIEGO , Sept. 16, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to c...

Shareholder rights law firm Robbins LLP is investigating whether Poseida Therapeutics, Inc. (NASDAQ: PSTX) and its officers and directors violated securities laws and engaged in unlawful business practices in connection with its initial public offering ("IPO"). Poseida is a clinical-stage b...

Poseida Therapeutics (NASDAQ: PSTX ) : Q2 GAAP EPS of -$2.28 misses by $1.13 . More news on: Poseida Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN DIEGO , Aug. 20, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced an operational ...

TRACON Pharmaceuticals gets FDA clearance for ENVASARC pivotal trial TRACON Pharmaceuticals ( TCON ) announced that the FDA has given its nod for a pivotal trial. The company had submitted the protocol as a part of its Investigational New Drug application with the FDA on July 15, 2020. T...

Gainers:  MICT (NASDAQ: MICT ) +52% . More news on: MICT, Inc., RISE Education Cayman Ltd, Forward Industries, Inc., Stocks on the move, , Read more ...